Please assess the completion status of the following clinical trial:

Trial Title: Feasibility of DPP-4 Inhibitor Therapy on Advanced Hybrid Closed Loop System

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients with type 1 diabetes (T1DM )for at least one year~* patients aged 12-27 years~* patients using MiniMed 780G AHCL system (Medtronic, Northridge, CA, USA) at least 6 months before the study~* patients with minimum daily insulin requirement of more than 8 units~* patients willingness and ability to adhere to the study protocol, access to the internet and a computer system that met requirements for uploading the study pump data.~Exclusion Criteria:~* patients with any microvascular or macrovascular complications~* pregnancy, lactation~* patients who had a point-of-care screening HbA1c \>10.0% (86 mmol/mol)~* patients with hypoglycemic unawareness or recurrent severe hypoglycemic episode in the last 6 months prior to recruitment~* patients with recurrent DKA (more than 2 episodes in the previous 6 months).~* patients with any chronic medical condition, current use of medications (other than insulin) that are known to affect blood glucose level.~* patients who had prior adverse reactions to the adjunctive agent

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 27 Years
- Healthy Volunteers: f

Study Arms:
- Dipeptidyl peptidase-4 inhibitors (Type: ACTIVE_COMPARATOR): Dipeptidyl peptidase-4 inhibitors with Iftar meal
- Control group (Type: NO_INTERVENTION): No Dipeptidyl peptidase-4 inhibitors intake with Iftar meal

Based on this trial design, predict the completion outcome and termination type (if applicable).